GILD ▲ +0.9% - Gilead Sciences, Inc. $GILD Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) 05-NOV-2026 10:00 AM ET